Reviewer's replyBMJ 1996; 313 doi: https://doi.org/10.1136/bmj.313.7063.1011a (Published 19 October 1996) Cite this as: BMJ 1996;313:1011
- Henry G Burger, Director
- Prince Henry's Institute of Medical Research, PO Box 5152, Clayton, Vic 3168, Australia
EDITOR,—I suggest that the facts be allowed to speak for themselves. Less than one fifth (not half) of my review alluded to “errors and misleading information.” I will deal with each in turn and leave readers to judge to whom such errors are correctly attributable.
Firstly, let me quote from the section of the book dealing with the medical management of hirsutism. “In recent years CPA [[cyproterone acetate]] has been most widely used with a lowdose oestrogen/anti-oestrogen combination containing 35 μg ethinyl oestradiol and 2 mg …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial